- Home
- SELF vs ADVM Comparison
SELF vs ADVM Comparison
Compare SELF & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SELF
- ADVM
- Stock Information
- Founded
- SELF 1983
- ADVM 2006
- Country
- SELF United States
- ADVM United States
- Employees
- SELF N/A
- ADVM N/A
- Industry
- SELF Real Estate Investment Trusts
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SELF Real Estate
- ADVM Health Care
- Exchange
- SELF Nasdaq
- ADVM Nasdaq
- Market Cap
- SELF 58.8M
- ADVM 66.3M
- IPO Year
- SELF N/A
- ADVM 2014
- Fundamental
- Price
- SELF $5.07
- ADVM $2.88
- Analyst Decision
- SELF
- ADVM Strong Buy
- Analyst Count
- SELF 0
- ADVM 4
- Target Price
- SELF N/A
- ADVM $19.75
- AVG Volume (30 Days)
- SELF 30.0K
- ADVM 73.0K
- Earning Date
- SELF 11-07-2025
- ADVM 11-03-2025
- Dividend Yield
- SELF 5.70%
- ADVM N/A
- EPS Growth
- SELF 9.99
- ADVM N/A
- EPS
- SELF 0.22
- ADVM N/A
- Revenue
- SELF $12,707,884.00
- ADVM $1,000,000.00
- Revenue This Year
- SELF N/A
- ADVM $1,836.70
- Revenue Next Year
- SELF N/A
- ADVM N/A
- P/E Ratio
- SELF $23.10
- ADVM N/A
- Revenue Growth
- SELF 4.08
- ADVM N/A
- 52 Week Low
- SELF $4.78
- ADVM $1.78
- 52 Week High
- SELF $5.89
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- SELF 41.94
- ADVM 45.17
- Support Level
- SELF $5.07
- ADVM $2.95
- Resistance Level
- SELF $5.22
- ADVM $3.23
- Average True Range (ATR)
- SELF 0.15
- ADVM 0.21
- MACD
- SELF -0.01
- ADVM -0.06
- Stochastic Oscillator
- SELF 8.69
- ADVM 1.39
About SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.